NCT02998450View on ClinicalTrials.gov

A Study of IMR-687 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 18, 2016

Primary Completion Date

July 8, 2017

Study Completion Date

July 8, 2017

Conditions
Sickle Cell DiseaseSickle-Cell; Hb-SCSickle Beta 0 Thalassemia
Interventions
DRUG

IMR-687

1 of 6 possible single doses administered orally following overnight fast

DRUG

Placebo Oral Capsule

Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.

Trial Locations (1)

66211

Quintiles, Overland Park

Sponsors
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

collaborator

Imara, Inc.

INDUSTRY

lead

Cardurion Pharmaceuticals, Inc.

INDUSTRY